HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Petroleum Fracking Firm’s OTC Sanitizer Production Pumps FDA The Wrong Way

Executive Summary

One of two US firms among five warned recently about problems with OTC sanitizers is a petroleum product business. Two of the other three warnings went to firms in Mexico, by far the predominant source of adulterated OTC sanitizers found in US since early 2020.

You may also be interested in...



Appetite In Congress For Adding Supplements To Pre-tax Savings Grows By Another House Bill

Reps. Brendan Boyle and Darin LaHood introduce Dietary Supplement Tax Fairness Ac to amend Internal Revenue Code to include some supplement products as qualified medical expenses.

In AstraZeneca-Sponsored Study, Digital App Corrects OTC Statin Self-Selection Problem

Using web app for self-selection was successful with more than 95% concordance for the primary endpoint comparing results obtained by participants and independent clinical assessments, say researchers led by cardiologist and consumer health innovation advocate Steven Nissen.

Will Novel NRT Interest Heat Up In US With First Clearance For ENDS Under Tobacco Control Act?

Without mentioning NRT space, FDA’s acceptance of one vape device and two replacement nicotine cartridges as tobacco products might reignite interest in proposals for ENDS or other novel products to be approved for smoking cessation claims. To gain clearance as tobacco products, the ENDS were shown to provide a benefit similar to efficacies required for an NRT.

Topics

UsernamePublicRestriction

Register

RS151832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel